Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
FAIL · Does not pass the screen
23.63 USD
Screen close, 2026-10-02 · not a live quote Last reviewed 5 days ago
Screened 2026-10-02 · the tape above runs as of 05:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 23.63 against the desk's fair-value range, base estimate 47.26, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price23.63 USD
Fair value47.26
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Markup23.62+0.0% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Mineralys Therapeutics, Inc. holds its Distribution at $23.63. The statistical read favours the sellers, held for 20 days.
As held on the ledger · 2026-10-02
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 20 days
Price at the screen
$23.63
Valuation
N/A trailing · -9.45 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.68
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
73.09%
Below 33%
Interest-bearing cash and securities are 73.1% of assets, above the one-third limit.
Fail
Receivables
26.13%
Below 49%
Money owed to the company is 26.1% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Mineralys Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 73% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-07. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-02 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus None. The average target sits +120% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Aldosterone pill story with no financials to back it
Picture a lab racing to fix hormone-driven blood pressure with one new pill. Mineralys sits at that early stage, yet the opportunity rating sits at none and the ethical screen flags insufficient data because basic ratios are missing.
The numbers show a company still burning cash, with a forward multiple at negative 12.9 times, zero profit margin and return on equity at negative 31 percent. Without a moat rating or consistent financial history the market price at 27 dollars versus a 52-dollar fair value offers no clear edge here.
Risks run high around clinical failure, dilution and the lack of any track record on governance or cash discipline. We pass until the data gaps close. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MLYS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markup$28.31+9.3%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it strong buy, with a mean price target of $48. Insiders have been net sellers over the past quarter.
2026-09-05Markup$25.89-4.4%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it strong buy, with a mean price target of $48.
2026-08-05Markup$27.09+14.7%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it strong buy, with a mean price target of $48.
2026-07-18Markup$23.62+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it strong buy, with a mean price target of $48.
2026-07-03Markup$23.62+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$23.62Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
